Sosei Heptares Expands UK R&D Operations to Second Site within Granta Park, Cambridge
TOKYO, Japan and CAMBRIDGE, United Kingdom, May 26, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (“the Company”; TSE: 4565), world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces it has expanded its UK R&D operations into a second site within Granta Park, Cambridge, to The Cori Building, previously occupied by Cancer Research UK.
The requirement for additional R&D space is being driven by the Company’s strategy to become a multi-program, early clinical stage business while continuing to be a discovery and development partner-of-choice for leading biopharmaceutical companies. As part of this strategy, Sosei Heptares is continuing to invest in enhancing its proprietary GPCR-focused discovery platform and expanding its R&D capacity to support the advancement of its in-house pipeline and partnered programs. The existing facility, The Steinmetz Building, will soon undergo remodeling to convert it exclusively to laboratory space.
The new facilities in The Cori Building will become home to Sosei Heptares’ expanded Translational Medicine team. This team is focused on taking a venture-like approach to the abundance of new discovery candidates generated by the Company’s discovery platform. The goal being to accelerate the prioritization and rapid progression of programs through Phase 1b/2a trials to establish clinical proof-of-concept; a key value inflection point to support future development and partnering opportunities.
Chris Cargill, President and CEO of Sosei Heptares, commented: “This expansion of our R&D capacity reflects the significant growth and development the Company has experienced in recent years, based on the excellent work we are doing with partners and collaborators. We now employ close to 200 expert R&D team members in Cambridge, which was just 130 when we first moved to Granta Park in 2018. Being established as a leading biopharmaceutical company in the Cambridge area has benefitted us greatly, allowing us to draw from the rich pool of R&D talent in the area. We are excited about the future for the Company and are equipped and motivated to capitalize on the huge potential of our GPCR-focused platform to deliver much-needed medicines to patients as quickly and efficiently as possible.”
About Sosei Heptares
We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.
For more information, please visit https://soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco
Enquiries:
Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, Chief Financial Officer
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Candelle Chong, SVP Investor Relations and Corporate Strategy
Japan: +81 (0)3 5210 3399 | United Kingdom: +44 (0)1223 949390 | IR@SoseiHeptares.com
MEDiSTRAVA Consulting (for International Media)
Mark Swallow, Frazer Hall, Eleanor Perkin
+44 (0)203 928 6900 | SoseiHeptares@medistrava.com
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
